Yuhan Corporation Wins 'Minister of Health and Welfare Award for Innovative Pharmaceutical Company'

Lazertinib Becomes the First Korean Anticancer Drug to Receive Global Regulatory Approval

Yuhan Corporation announced on the 28th that it received the Minister of Health and Welfare Award at the '2025 Health Industry Performance Exchange Meeting.'

Jo Wookje, CEO of Yuhan Corporation (right), is receiving the Minister of Health and Welfare Award from Jung Kyungsil, Director of Medical Policy at the Ministry of Health and Welfare, at the "2025 Health Industry Performance Exchange Meeting." Yuhan Corporation

Yuhan Corporation achieved a milestone by obtaining approval from the U.S. Food and Drug Administration (FDA) for 'Lazertinib' (domestic product name 'Leclaza'), a third-generation non-small cell lung cancer treatment developed with domestic technology, marking the first time a Korean anticancer drug has received such approval.

This event, hosted by the Ministry of Health and Welfare and organized by the Korea Health Industry Development Institute, was held in conjunction with the 30th anniversary celebration of health and medical research and development (R&D).

The Innovative Pharmaceutical Company Certification is a system in which the government certifies domestic pharmaceutical companies with R&D-driven innovation capabilities, such as new drug development and platform technology establishment. Among these, companies that have contributed to public health improvement and the advancement of the pharmaceutical industry are selected and recognized annually.

At the event, Lee Junhyeong, Director of Yuhan Corporation's R&D Strategy Team, presented the company's achievements in open innovation and 'Leclaza.' The presentation focused on the background for adopting open innovation, such as increasing the success rate of new drug development, and highlighted the success story of Leclaza achieved through this approach.

A Yuhan Corporation representative stated, "We believe this award is the result of Yuhan Corporation's continuous efforts toward patient-centered innovation," adding, "We will continue to strive as a company that develops innovative new drugs and contributes to the health and happiness of humanity."

This content was produced with the assistance of AI translation services.